Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

NIO

NIO Raises $738M in Convertible Note

56 Antai Street, Shanghai 200120, ChinaSeptember 12, 20242 min read
Employees
13000+

NIO Raises $738M in Convertible Note


NIO has successfully raised $738M in a Convertible Note at a $14B valuation led by Tencent, Hillhouse Capital, Temasek Holdings, Baillie Gifford, BlackRock.


Company Overview


NIO is a Automotive company headquartered in 56 Antai Street, Shanghai 200120, China, founded in 2014 with 13000+ employees.


Electric vehicle manufacturer


Fundraising Details


  • Amount Raised: $738M
  • Round Type: Convertible Note
  • Valuation: $14B
  • Date: 2024-09-12
  • Investors: Tencent, Hillhouse Capital, Temasek Holdings, Baillie Gifford, BlackRock

About NIO


Electric vehicle manufacturer The company is positioned in the Automotive sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 56 Antai Street, Shanghai 200120, China
  • Founded: 2014
  • Team Size: 13000+
  • Industry: Automotive

What This Means


This funding round demonstrates strong investor confidence in NIO's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Automotive sector continues to attract significant investment as companies innovate to meet evolving market demands. NIO's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $14B valuation marks an important milestone for NIO, positioning the company among notable players in the Automotive industry.


Looking Ahead


With this new capital, NIO is well-positioned to execute on its growth strategy and continue building innovative solutions in the Automotive space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-09-12. For more information about NIO, visit their headquarters at 56 Antai Street, Shanghai 200120, China.

Company Info

Headquarters
56 Antai Street, Shanghai 200120, China
Founded
2014
Team Size
13000+

Topics

Fundraising(2912)Automotive(414)Convertible NoteNIO

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free